CHELSEA BOHAC: Open Payments
NPI 1780108175 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$691 in 39 payments from 12 companies in 2025. Trend: 2023 $730 · 2024 $1,186 · 2025 $691
Food & beverage: $691
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $335 |
| Novo Nordisk Inc | 4 | $81 |
| Dexcom, Inc. | 2 | $55 |
| Antares Pharma, Inc. | 2 | $36 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| SHIELD THERAPEUTICS INC | 2 | $31 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $16 |
Products named: VRAYLAR, UBRELVY, Ozempic, Dexcom G6 Transmitter, XYOSTED, ACCRUFER, TRELEGY ELLIPTA, REXULTI.
Industry payments across TX — which companies pay providers there.
